Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure.

[1]  T. McDonagh,et al.  N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.

[2]  R. Berger,et al.  Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  D. vesely,et al.  Natriuretic peptides and acute renal failure. , 2003, American journal of physiology. Renal physiology.

[4]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[5]  J. McMurray,et al.  N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure , 2003, Heart.

[6]  H. Singer,et al.  Normal values of B type natriuretic peptide in infants, children, and adolescents , 2003, Heart.

[7]  P. Hildebrandt,et al.  The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population , 2003, Heart.

[8]  C. Frampton,et al.  B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.

[9]  J. Rehfeld,et al.  Increased cardiac BNP expression associated with myocardial ischemia , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  H. Ruskoaho.  Cardiac hormones as diagnostic tools in heart failure. , 2003, Endocrine reviews.

[11]  Richard Kamin,et al.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.

[12]  M. Desnos,et al.  Bedside B‐type natriuretic peptide and functional capacity in chronic heart failure , 2003, European journal of heart failure.

[13]  M. Jessup,et al.  Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  S. Gottlieb,et al.  A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. , 2002, American heart journal.

[15]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[16]  A. Morris,et al.  Screening for and treatment of left-ventricular abnormalities in diabetes mellitus , 2002, The Lancet.

[17]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[18]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[19]  A. Morris,et al.  Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths , 2002, The Lancet.

[20]  D. Morrow,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .

[21]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[22]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[23]  J. Mair,et al.  The Impact of Cardiac Natriuretic Peptide Determination on the Diagnosis and Management of Heart Failure , 2001, Clinical chemistry and laboratory medicine.

[24]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[25]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[26]  C. Zoccali,et al.  Diagnostic potential of cardiac natriuretic peptides in dialysis patients. , 2001, Kidney international.

[27]  J. Ketelslegers,et al.  Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. , 2000, Journal of cardiac failure.

[28]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[29]  J G Turner,et al.  Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction , 1999, Heart.

[30]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[31]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[32]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[33]  A. Struthers,et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.

[34]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[35]  J. Rehfeld,et al.  Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.